Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 270-281

  Hoeppner, Luke H ^a   Wang, Ying ^a   Sharma, Anil ^a   Javeed, Naureen ^a   Van Keulen, Virginia P ^a   Wang, Enfeng ^a   Yang, Ping ^b   Roden, Anja C ^b   Peikert, Tobias ^a,b   Molina, Julian R ^b   Mukhopadhyay, Debabrata ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Angiogenesis; Cabergoline; Dopamine; Dopamine D2 receptor agonists; Lung cancer; VEGF

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG CANCER; LUNG ENDOTHELIUM; MEDICAL HISTORY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SMOKING; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

MURINAE;

ANIMALS; DOPAMINE D2 RECEPTOR ANTAGONISTS; ENDOTHELIUM, VASCULAR; HUMANS; LUNG NEOPLASMS; MICE; MYELOID CELLS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, DOPAMINE D2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920398036     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.08.008     Document Type: Article

References (51)

1. Alberg A.J., Shopland D.R., Cummings K.M. The 2014 Surgeon General's report: commemorating the 50th Anniversary of the 1964 Report of the Advisory Committee to the US Surgeon General and updating the evidence on the health consequences of cigarette smoking. Am. J. Epidemiol. 2014, 179:403-412.
2. Basu S., Nagy J.A., Pal S., Vasile E., Eckelhoefer I.A., Bliss V.S., Manseau E.J., Dasgupta P.S., Dvorak H.F., Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 2001, 7:569-574.
3. Basu S., Sarkar C., Chakroborty D., Nagy J., Mitra R.B., Dasgupta P.S., Mukhopadhyay D. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res. 2004, 64:5551-5555.
4. Benowitz N.L. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol. 2009, 49:57-71.
5. Bhandarkar S.S., Jaconi M., Fried L.E., Bonner M.Y., Lefkove B., Govindarajan B., Perry B.N., Parhar R., Mackelfresh J., Sohn A., Stouffs M., Knaus U., Yancopoulos G., Reiss Y., Benest A.V., Augustin H.G., Arbiser J.L. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J.Clin. Invest. 2009, 119:2359-2365.
6. Bhattacharya R., Sinha S., Yang S.P., Patra C., Dutta S., Wang E., Mukhopadhyay D. The neurotransmitter dopamine modulates vascular permeability in the endothelium. J.Mol. Signal. 2008, 3:14.
7. Burns D.M. Tobacco-related diseases. Semin. Oncol. Nurs. 2003, 19:244-249.
8. Campa D., Zienolddiny S., Lind H., Ryberg D., Skaug V., Canzian F., Haugen A. Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer. Lung Cancer 2007, 56:17-23.
9. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
10. Cetin K., Ettinger D.S., Hei Y.J., O'Malley C.D. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, epidemiology and end results program. Clin. Epidemiol. 2011, 3:139-148.
11. Chakroborty D., Chowdhury U.R., Sarkar C., Baral R., Dasgupta P.S., Basu S. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J.Clin. Invest. 2008, 118:1380-1389.
12. Chen J., Jiang R., Garces Y.I., Jatoi A., Stoddard S.M., Sun Z., Marks R.S., Liu Y., Yang P. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer 2010, 67:221-226.
13. Chen J., Qi Y., Wampfler J.A., Jatoi A., Garces Y.I., Busta A.J., Mandrekar S.J., Yang P. Effect of cigarette smoking on quality of life in small cell lung cancer patients. Eur. J. Cancer 2012, 48:1593-1601.
14. Corzo C.A., Cotter M.J., Cheng P., Cheng F., Kusmartsev S., Sotomayor E., Padhya T., McCaffrey T.V., McCaffrey J.C., Gabrilovich D.I. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J.Immunol. 2009, 182:5693-5701.
15. Ellis P.M., Al-Saleh K. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit. Rev. Oncol. Hematol. 2012, 84:47-58.
16. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
17. Garces Y.I., Yang P., Parkinson J., Zhao X., Wampfler J.A., Ebbert J.O., Sloan J.A. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest 2004, 126:1733-1741.
18. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J.Natl. Cancer Inst. 1999, 91:1194-1210.
19. Heeschen C., Weis M., Aicher A., Dimmeler S., Cooke J.P. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J.Clin. Invest. 2002, 110:527-536.
20. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
21. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., Langer C.J., DeVore R.F., Gaudreault J., Damico L.A., Holmgren E., Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J.Clin. Oncol. 2004, 22:2184-2191.
22. Kaner R.J., Ladetto J.V., Singh R., Fukuda N., Matthay M.A., Crystal R.G. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am. J. Respir. Cell Mol. Biol. 2000, 22:657-664.
23. Kazi A.S., Lotfi S., Goncharova E.A., Tliba O., Amrani Y., Krymskaya V.P., Lazaar A.L. Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 286:L539-L545.
24. Korpanty G., Smyth E., Sullivan L.A., Brekken R.A., Carney D.N. Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp. Biol. Med. (Maywood) 2010, 235:3-9.
25. Lahm T., Crisostomo P.R., Markel T.A., Wang M., Lillemoe K.D., Meldrum D.R. The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. Shock 2007, 28:4-14.
26. Lambrechts D., Buysschaert I., Zanen P., Coolen J., Lays N., Cuppens H., Groen H.J., Dewever W., van Klaveren R.J., Verschakelen J., Wijmenga C., Postma D.S., Decramer M., Janssens W. The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema. Am. J. Respir. Crit. Care Med. 2010, 181:486-493.
27. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
28. Lynch T.J., Adjei A.A., Bunn P.A., Eisen T.G., Engelman J., Goss G.D., Haber D.A., Heymach J.V., Janne P.A., Johnson B.E., Johnson D.H., Lilenbaum R.C., Meyerson M., Sandler A.B., Sequist L.V., Settleman J., Wong K.K., Hart C.S. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin. Cancer Res. 2006, 12:4365s-4371s.
29. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., Sebastian M., Neal J., Lu H., Cuillerot J.M., Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J.Clin. Oncol. 2012, 30:2046-2054.
30. Nasevicius A., Larson J., Ekker S.C. Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast 2000, 17:294-301.
31. Natale R.B. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J.Thorac. Oncol. 2008, 3:S128-S130.
32. Perry B.N., Govindarajan B., Bhandarkar S.S., Knaus U.G., Valo M., Sturk C., Carrillo C.O., Sohn A., Cerimele F., Dumont D., Losken A., Williams J., Brown L.F., Tan X., Ioffe E., Yancopoulos G.D., Arbiser J.L. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J.Invest. Dermatol. 2006, 126:2316-2322.
33. Pusztaszeri M.P., Seelentag W., Bosman F.T. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J.Histochem. Cytochem. 2006, 54:385-395.
34. Saccone N.L., Culverhouse R.C., Schwantes-An T.H., Cannon D.S., Chen X., Cichon S., Giegling I., Han S., Han Y., Keskitalo-Vuokko K., Kong X., Landi M.T., Ma J.Z., Short S.E., Stephens S.H., Stevens V.L., Sun L., Wang Y., Wenzlaff A.S., Aggen S.H., Breslau N., Broderick P., Chatterjee N., Chen J., Heath A.C., Heliovaara M., Hoft N.R., Hunter D.J., Jensen M.K., Martin N.G., Montgomery G.W., Niu T., Payne T.J., Peltonen L., Pergadia M.L., Rice J.P., Sherva R., Spitz M.R., Sun J., Wang J.C., Weiss R.B., Wheeler W., Witt S.H., Yang B.Z., Caporaso N.E., Ehringer M.A., Eisen T., Gapstur S.M., Gelernter J., Houlston R., Kaprio J., Kendler K.S., Kraft P., Leppert M.F., Li M.D., Madden P.A., Nothen M.M., Pillai S., Rietschel M., Rujescu D., Schwartz A., Amos C.I., Bierut L.J. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet. 2010, 6.
35. Saha B., Mondal A.C., Basu S., Dasgupta P.S. Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an invitro analysis. Int. Immunopharmacol. 2001, 1:1363-1374.
36. Sarkar C., Chakroborty D., Chowdhury U.R., Dasgupta P.S., Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin. Cancer Res. 2008, 14:2502-2510.
37. Schuller H.M. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?. Nat. Rev. Cancer 2009, 9:195-205.
38. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
39. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
40. Sinha S., Vohra P.K., Bhattacharya R., Dutta S., Mukhopadhyay D. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2. J.Cell Sci. 2009, 122:3385-3392.
41. Smith N.R., Baker D., James N.H., Ratcliffe K., Jenkins M., Ashton S.E., Sproat G., Swann R., Gray N., Ryan A., Jurgensmeier J.M., Womack C. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin. Cancer Res. 2010, 16:3548-3561.
42. Spitz M.R., Amos C.I., Dong Q., Lin J., Wu X. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J.Natl. Cancer Inst. 2008, 100:1552-1556.
43. Styn M.A., Nukui T., Romkes M., Perkins K., Land S.R., Weissfeld J.L. The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B:254-261.
44. Tilan J., Kitlinska J. Sympathetic neurotransmitters and tumor angiogenesis-link between stress and cancer progression. J.Oncol. 2010, 2010:539706.
45. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., McMiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N.Engl. J. Med. 2012, 366:2443-2454.
46. Tournier J.M., Birembaut P. Nicotinic acetylcholine receptors and predisposition to lung cancer. Curr. Opin. Oncol. 2011, 23:83-87.
47. Voelkel N.F., Vandivier R.W., Tuder R.M. Vascular endothelial growth factor in the lung. Am. J. Physiol. Lung Cell Mol. Physiol 2006, 290:L209-L221.
48. Wang Y., Pereira E.F., Maus A.D., Ostlie N.S., Navaneetham D., Lei S., Albuquerque E.X., Conti-Fine B.M. Human bronchial epithelial and endothelial cells express alpha7 nicotinic acetylcholine receptors. Mol. Pharmacol. 2001, 60:1201-1209.
49. Wu X., Hudmon K.S., Detry M.A., Chamberlain R.M., Spitz M.R. D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: a lung cancer case-control study. Cancer Epidemiol. Biomarkers Prev. 2000, 9:1021-1026.
50. Yang Y., Zhang Y., Cuevas S., Villar V.A., Escano C., D.A L., Yu P., Grandy D.K., Felder R.A., Armando I., Jose P.A. Paraoxonase 2 decreases renal reactive oxygen species production, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of NADPH oxidase. Free Radic. Biol. Med. 2012, 53:437-446.
51. Zaroslinski J.F., Possley L.H., Schwartz R.A., Morris R.N., Carone F.A., Browne R.K. The pharmacology and subacute toxicology of dopamine. Proc. R. Soc. Med. 1977, 70(Suppl.2):2-6.